2.5 g/m2 of Pivanex administered intravenously over 6 hours daily on Days 1 – 3. Treatment will be repeated every 21 days

Uterine sarcoma (MES-SA, MES-DX5), Human prostate carcinoma (PC-3), colon cancer (HT-29) and myelocytic leukemia (HL-60, HL-60 MX2) cell lines were used for activity evaluation. Cells in 200-250 µL growth medium at a density of (2.5-5) × 10^4 cells/mL were seeded in tissue culture 96-well plates (in triplicate), for 24 h, without FCS. They were then exposed to different concentrations (titration) of the AN-9 (in medium containing 10% serum) under sterile incubation conditions. Two methods were used for proliferation measurements: (a) The Hoechst assay was used to examine the proliferation of the solid tumor cell lines HT-29, PC3, MES-SA, and MES-SA DX5. After 4 days of incubation with the AN-9, the samples were rinsed with PBS and fixed by the addition of 100 µL of 70% ethanol. After 0.5 h, the ethanol was decanted and 200 µL (10 mg/mL) of the DNA binding dye Hoechst reagent, solubilized in PBS, was added. The fluorescence emitted by the samples was measured at 390-460 nm; (b) The Alamar blue reagent (20 µL), used for HL-60, HL-60/MX2, , incubated at 37 °C, was added 24 h prior to termination of treatment, and the fluorescence was measured at 390 nm excitation and 460 nm emission (FluoStar fluorometer).